346 results on '"Goyal, Subir"'
Search Results
52. Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
53. Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
54. Differences in Failure-free Survival Post Salvage Radiotherapy Guided by Conventional Imaging Versus18F-fluciclovine PET/CT in Post-prostatectomy Patients: a Post-hoc Sub-stratification Analysis of the EMPIRE-1 Trial
55. 1033 Stem-like CD8 T-cells residing in antigen presenting immune niches are prognostic for local control in brain metastases and are sustained following radiation therapy
56. RADT-21. PATTERNS OF CARE AND OUTCOMES IN PEDIATRIC HIGH-GRADE GLIOMA PATIENTS ENROLLED IN THE PEDIATRIC PROTON/PHOTON CONSORTIUM REGISTRY
57. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome
58. 478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI)
59. Defining the Reliability of Bladder Scan in Obese Patients with Postoperative Urinary Retention
60. The impact of operability status on outcomes in patients with T4 larynx cancer undergoing larynx preservation
61. Construct validation and comparison of a novel postoperative quality-of-life metric and the Short Form-36 in colorectal surgery patients
62. PO0403: Effect of Androgen Deprivation Therapy in Addition to Brachytherapy-Based Dose Escalated Radiation Therapy for Men with Unfavorable Intermediate Risk Prostate Cancer
63. A review of hepatic epithelioid hemangioendothelioma—Analyzing patient characteristics and treatment strategies
64. Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomography–Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects
65. LOCL-05 CEREBRAL METASTATIC LUNG CARCINOMA: EFFECT OF ALK- AND EGFR-MUTATION STATUS AND SURGICAL MANAGEMENT UPON CLINICAL OUTCOME
66. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
67. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
68. Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia
69. Dexamethasone and brain metastasis-infiltrating CD8+ T cells.
70. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center
71. Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial.
72. Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
73. Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
74. Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).
75. Impact of rectal spacer on toxicity reduction in men treated with proton versus photon therapy.
76. Impact of Concurrent Gabapentin or Pregabalin With High‐Dose Melphalan in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant
77. Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.
78. The impact of CA 19-9 on survival in patients with clinical stage I pancreatic cancer.
79. Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma
80. 970: EVALUATION OF THE USE OF MODAFINIL IN CRITICALLY ILL PATIENTS: A RETROSPECTIVE CHART REVIEW
81. Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
82. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis
83. Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel
84. 18 Systemic immune profiling of advanced biliary tract cancer patients defines altered cytokines and immune cell populations
85. Racial differences in clinical presentation and outcomes in mycosis fungoides and Sézary syndrome in the United States: a large singe center retrospective analysis
86. Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis
87. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors
88. Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
89. Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation
90. Intellectual functioning among case‐matched cohorts of children treated with proton or photon radiation for standard‐risk medulloblastoma
91. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
92. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
93. Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
94. Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
95. Association of suboptimal lymph node yield with inferior survival in resected stage 1 colon cancer patients.
96. Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.
97. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer
98. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance
99. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node–Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy
100. Treatment Patterns and Clinical Outcomes of Patients with Sézary Syndrome at Emory University
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.